Single-port Versus Multi-port Robotic Surgery for Rectal Cancer

NCT06824688 · tracked via the Priya Life Science China tracker

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase

Not applicable

Started

2025-04-26

Last updated

2026-08-04

Condition(s) studied

Rectal Cancer PatientsRobotic Surgical Procedures

Investigational drug(s) / intervention(s)

Single-port robotic total mesorectal excisionMulti-port robotic total mesorectal excision

Single-port robotic total mesorectal excision: Single-port robotic total mesorectal excision

Multi-port robotic total mesorectal excision: Multi-port robotic total mesorectal excision

Study summary

Single-port versus multi-port robotic surgery for rectal cancer

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion criteria comprised: (1) MRI-confirmed distal tumor margin \<15 cm from the anal verge, (2) biopsy-proven adenocarcinoma, (3) clinical stage I-III (AJCC 8th edition) with potential downstaging post-neoadjuvant therapy, (4) intent-to-treat with sphincter preservation and primary anastomosis, (5) documented informed consent, and (6) adult patients (≥18 years).

Primary outcome measure(s)

Incidence of perioperative complications — Intraoperative and postoperative 30 days
Perioperative complications will be described using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v. 4.03 criteria. Complications will refer to any medical occurrence directly attributed to the surgical procedure during and within the first 30 days.
Number of participants with conversion procedures — Date of surgery (Day 1)
The number of patients converted from robotic to open or laparoscopic surgery

Trial sites (1)

Facility	City	Region	Status
Huichao Zheng	Chongqing	China	Recruiting

More Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials in China

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Recruiting

CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer Active, not recruiting

Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases Starting soon

LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer Starting soon

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis Recruiting

Other trials for the same condition

Site of Tracheal Extubation and Operating Room Efficiency During Robot-assisted Surgery Recruiting

Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study Active, not recruiting

Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial Recruiting

Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision Recruiting

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06824688 on ClinicalTrials.gov ↗ ← All trials in China